Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

Pharmacological Reviews(2023)10.1124/pharmrev.123.000906Source: DataRank Database

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor is a research paper published in Pharmacological Reviews (2023). On theSindex it has a DataRank of 0. It has been cited 59 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access59 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 6.81)OA: bronzeTopics (55)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Yuesheng Zhang ORCID

Live enrichment

PubMed:37339882 PMC:PMC10595022 OpenAlex:https://openalex.org/W4381328302

NCI NIH HHS

Grant: R01 CA244601

NCI NIH HHS

Grant: R01 CA215093

National Institutes of Health

Grant: 5R01CA244601-05

Overcoming Drug Resistance in HER2-positive Breast Cancer

National Institutes of Health

Grant: 7R01CA215093-06

Combating Cetuximab Resistance in Colorectal Cancer

FWCI

6.81

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronzeLicense: CC BY NC

journalhttps://pharmrev.aspetjournals.org/content/pharmrev/early/2023/06/20/pharmrev.123.000906.full.pdf

publisherhttps://pharmrev.aspetjournals.org/content/pharmrev/early/2023/06/20/pharmrev.123.000906.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0031699724008007?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0031699724008007?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/pharmrev.123.000906

Fields of Study

HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies03 medical and health sciences0302 clinical medicineHumansProtein Kinase InhibitorsErbB ReceptorsNeoplasmsAntibodies, MonoclonalPhosphorylationDrug Resistance, NeoplasmAntineoplastic AgentsMutation

MeSH Terms

Antibodies, MonoclonalAntineoplastic AgentsHumansMutationNeoplasmsPhosphorylationDrug Resistance, NeoplasmProtein Kinase InhibitorsErbB Receptors

Keywords

Cancer researchTyrosine kinaseReceptor tyrosine kinaseEpidermal growth factor receptorROR1EGFR inhibitorsErlotinibGrowth factor receptorCyclin-dependent kinase 8GefitinibKinaseBiologyPharmacologyCancerPlatelet-derived growth factor receptorMedicineSignal transductionReceptorCell biologyInternal medicineBiochemistryGrowth factorErbB ReceptorsDrug Resistance, NeoplasmNeoplasmsMutationHumansAntibodies, MonoclonalAntineoplastic AgentsReview ArticlePhosphorylationProtein Kinase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being